Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- GSK Clinical Trials
GlaxoSmithKline
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
159 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Buenos Aires, Argentina
Nicolas ItcoviciRecruiting - Gsk Investigational Site
Buenos Aires, Argentina
Pablo DoreskiRecruiting - Gsk Investigational Site
Córdoba, Argentina
Fernando BordeseRecruiting - Gsk Investigational Site
Quilmes, Argentina
Julian MerelesRecruiting - Gsk Investigational Site
Santa Fe, Argentina
Martin MailloRecruiting
- Gsk Investigational Site
Coffs Harbour, New South Wales, Australia
Olga VoloshynaRecruiting - Gsk Investigational Site
Maroubra, New South Wales, Australia
Mark AryaRecruiting - Gsk Investigational Site
Westmead, New South Wales, Australia
Stephen MilneRecruiting - Gsk Investigational Site
Midland, Western Australia, Australia
David MannersRecruiting
- Gsk Investigational Site
Graz, Austria
Katrin MilgerRecruiting - Gsk Investigational Site
Innsbruck, Austria
Thomas SonnweberRecruiting - Gsk Investigational Site
Klagenfurt, Austria
Daniel DobererRecruiting - Gsk Investigational Site
Linz, Austria
Christopher LambersRecruiting - Gsk Investigational Site
Linz, Austria
Michael WuertzRecruiting - Gsk Investigational Site
Linz, Austria
Andreas HornerRecruiting - Gsk Investigational Site
Vienna, Austria
Marco IdzkoRecruiting
- Gsk Investigational Site
Dupnitsa, Bulgaria
Elena GyuzelevaRecruiting - Gsk Investigational Site
Haskovo, Bulgaria
Veselin KalfovRecruiting - Gsk Investigational Site
Lovech, Bulgaria
Mihail KirovRecruiting - Gsk Investigational Site
Montana, Bulgaria
Lidia NikolchevaRecruiting - Gsk Investigational Site
Montana, Bulgaria
Vanko VankovRecruiting - Gsk Investigational Site
Pleven, Bulgaria
Mariya TodorovaRecruiting - Gsk Investigational Site
Rousse, Bulgaria
Nikolay NikolaevRecruiting - Gsk Investigational Site
Rousse, Bulgaria
Hristo MetevRecruiting - Gsk Investigational Site
Sofia, Bulgaria
Kiril PalaveevRecruiting - Gsk Investigational Site
Sofia, Bulgaria
Georgi HinkovRecruiting
- Gsk Investigational Site
Jindřichův Hradec, Czechia
Petr Kopecký jrRecruiting - Gsk Investigational Site
Kralupy nad Vltavou, Czechia
Otakar HokynarRecruiting - Gsk Investigational Site
Nymburk, Czechia
Sarka KlimesovaRecruiting - Gsk Investigational Site
Prague, Czechia
Zuzana BouckovaRecruiting - Gsk Investigational Site
Varnsdorf, Czechia
Milan SklenarRecruiting
- Gsk Investigational Site
Munich, Bavaria, Germany
Korkut AvsarRecruiting - Gsk Investigational Site
Offenbach, Hesse, Germany
Florieke BerfeloRecruiting - Gsk Investigational Site
Rheine, North Rhine-Westphalia, Germany
Marc HoeffgenRecruiting - Gsk Investigational Site
Bendorf, Germany
Olaf SchmidtRecruiting - Gsk Investigational Site
Berlin, Germany
Bjoern MartensRecruiting - Gsk Investigational Site
Berlin, Germany
Thomas LienertRecruiting - Gsk Investigational Site
Berlin, Germany
Ishak TeberRecruiting - Gsk Investigational Site
Berlin, Germany
Jens DriemertRecruiting - Gsk Investigational Site
Berlin, Germany
Thomas SchultzRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Jun 2025
- Primary completion
- 21 Aug 2029
- Completion
- 21 Aug 2029
- Last update posted
- 9 Apr 2026
- Registered enrollment
- 960
- Registry id
- NCT06961214
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.